• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Methods and compositions are provided for objectively characterizing a pathological lesion in a patient. The method comprises: introducing into the patient a contrast enhancing agent; subjecting the patient to at least one of magnetic resonance imaging and computed tomography to obtain an image; and applying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum. The method may further comprise comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for the pathological lesion. In one example, the methods and compositions may be useful for identifying and objectively characterizing amyloid plaque deposits characteristic of Alzheimer's Disease.
    公开号:AU2013209437A1
    申请号:U2013209437
    申请日:2013-01-20
    公开日:2014-05-15
    发明作者:Ananth Annapragada；Zbigniew STAROSOLSKI
    申请人:Ananth Annapragada；Zbigniew STAROSOLSKI；
    IPC主号:G06K9-62
    专利说明:
    WO 2013/110013 PCT/US2013/022336 METHODS AND COMPOSITIONS FOR OBJECTIVELY CHARACTERIZING MEDICAL IMAGES CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority from U.S. Provisional Patent Application No. 61/589,165, filed on January 20, 2012, which is incorporated by reference herein in its entirety. BACKGROUND [0002] Medical images are routinely acquired in the screening, diagnosis, and treatment of many diseases. A variety of imaging techniques exist, including, for example, magnetic resonance imaging (MRI), X-ray, computed tomography (CT), ultrasonic imaging, and nuclear medicine. In particular, MRI, X-ray, and CT produce images of anatomical structures, such as pathological lesions. [0003] One limitation of current imaging techniques is that few methods exist to objectively characterize the structure (in the case of pathological lesions) imaged without the need for human interpretation. One attempted method for objective image analysis is the 2-dimensional (2-D) autocorrelation function. However, for a variety of reasons, the 2-D autocorrelation function is practically meaningless in the context of a 3-dimensional (3-D) image. [0004] A system and method are needed for using a morphometric index-a measure of the morphology of certain medical images-that objectively characterizes the images. Thus, a system and method are provided herein for using the 3-D autocorrelation function to objectively characterize medical images. 1 WO 2013/110013 PCT/US2013/022336 SUMMARY [0005] In one embodiment, a method for characterizing a pathological lesion in a patient is provided, the method comprising: introducing into the patient a contrast enhancing agent; subjecting the patient to at least one of MRI and CT to obtain an image; and applying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum. The method may further comprise comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3 D autocorrelation spectrum that is characteristic for the pathological lesion. [0006] In another embodiment, a method for detecting amyloid plaque deposition on a patient's brain is provided, the method comprising: introducing into the patient a nanoparticle contrast enhancing agent; subjecting the patient to at least one of MRI and CT to obtain an image; and applying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum. The method may further comprise comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for amyloid plaque deposition on a brain. [0007] In another embodiment, a method for diagnosing Alzheimer's Disease in a patient is provided, the method comprising: introducing into the patient a nanoparticle contrast enhancing agent, the nanoparticle contrast enhancing agent comprising: liposomes, the liposomes comprising: 1,2-dipalmitoyl-sn-glycero-3 phosphocholine (DPPC), Gd-DTPA bis(stearylamide) (Gd-DTPA-BSA), cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(-poly(ethylene glycol))-2000] (mPEG2000-DSPE); subjecting the patient to MRI to obtain an image; and applying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum. The method may further comprise 2 WO 2013/110013 PCT/US2013/022336 comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for Alzheimer's Disease. BRIEF DESCRIPTION OF THE DRAWINGS [0008] In the accompanying figures, experimental data are given that, together with the detailed description provided below, describe example embodiments of the claimed invention. [0009] Figure 1 illustrates a cerebral magnetic resonance angiography in a C57BL/6 mouse. [0010] Figure 2 illustrates a 2-dimensional view of a subdomain of the brain vasculature shown in the cerebral magnetic resonance angiography of Figure 1. [0011] Figure 3a illustrates results of multrifractality and lacunarity analysis of the subdomain of Figure 2, wherein the subdomain has been digitally manipulated to introduce synthetic "holes" that simulate amyloid plaques. [0012] Figure 3b illustrates results of 2-D autocorrelation analyses of the subdomain of Figure 2, wherein the subdomain has been digitally manipulated to introduce synthetic "holes" that simulate amyloid plaques. [0013] Figure 4 illustrates 3-D autocorrelation functions of longitudinal relaxation time (TI) vasculature maps of amyloid positive mice (A-C) and amyloid negative mice (D-F). [0014] Figure 5 illustrates 3-D autocorrelation analyses of cranial vasculature images, wherein the images have been randomly digitally manipulated to introduce synthetic "holes" that simulate amyloid plaques. [0015] Figure 6 illustrates 3-D autocorrelation analyses of cranial vasculature images, wherein the images have been digitally manipulated to introduce synthetic "holes" that simulate amyloid plaques along the vasculature structures in the tissues. 3 WO 2013/110013 PCT/US2013/022336 DETAILED DESCRIPTION [0016] Methods and compositions for objectively characterizing pathological lesion(s) in a patient are provided. In one embodiment, the method comprises introducing into the patient a contrast enhancing agent; subjecting the patient to at least one of MRI and CT to obtain an image; and applying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum. The method may further comprise comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for the pathological lesion(s). [0017] Autocorrelation in higher dimensions is defined as: _3' X '( "'Y [0018] This quantity is a direct measure of the value of a function S at any location in the domain with respect to its value at some distance -C away. From its origins as a method of analyzing time, -c, the spatial displacement, is also called the "delay" coordinate. This formally definitive expression, however, is numerically very intensive, with the number of operations per function evaluation scaling as rl2, where Ta is the number of delay intervals to be used. Thus, 1-D data is relatively straightforward to compute, but 2-D data scales as i4, and 3-D data as g 6 , leading to onerous computational demands. For higher order autocorrelation functions, the Wiener-Khinchin theorem becomes necessary, which shows that the autocorrelation is equal to the Fourier transform of the power spectrum of the original function. Using the Fast Fourier Transform algorithm, the computational load scales as 2 a log T, a much more practicable situation. 4 WO 2013/110013 PCT/US2013/022336 [0019] The physical interpretation of the autocorrelation function is straightforward. It essentially measures the behavior of a function at a certain distance from any starting point in the domain. Thus, at a zero delay coordinate, the autocorrelation is always 1, since the function at any point is equal to itself. Purely random functions display {A : A,= 0 = 1; Ao = 01. Inherent decays and periodicities in functions are amplified in the autocorrelation, and automatically scale to a range of {0,11. [0020] In one exemplary embodiment of the method, amyloid plaque deposition on a patient's brain may be detected. Thus, a nanoparticle contrast enhancing agent is introduced to the patient; and the patient is subjected to at least one of MRI and CT to obtain an image. [0021] If the imaging technique of choice is MRI, the contrast enhancing agent may comprise an MR-effective nanoparticle contrast enhancing agent such as a gadolinium complex having long circulating properties, such as, for example, the dual gadolinium liposomal agent described in Ghaghada, K.B. et al., "New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging." PloS One, 4(10), e7628. Doi: 10.1371/journal.pone.0007628, which is incorporated by reference herein in its entirety. In one embodiment, the dual gadolinium liposomal agent is less than about 200 nm in average diameter. In one embodiment, the dual gadolinium liposomal agent is less than about 175 nm in average diameter. In one embodiment, the dual gadolinium liposomal agent is less than about 150 nm in average diameter. In one embodiment, the dual gadolinium liposomal agent is about 100 nm in average diameter. Another suitable MR-effective agent may include Ablavar@ (gadofosveset trisodium) (manufactured by Lantheus Medical Imaging, Inc. located in N. Billerica, Massachusetts, U.S.A.), a stable gadolinium diethylenetriaminepentaacetic acid 5 WO 2013/110013 PCT/US2013/022336 (GdDTPA) chelate derivative with a diphenylcyclohexylphosphate group. Another suitable MR-effective agent may include an agent comprising liposomes, the liposomes comprising: a phospholipid (e.g., DPPC); a phospholipid that is derivatized with a polymer (e.g., a PEGylated phospholipid such as mPEG2000 DSPE); and cholesterol, wherein the liposomes encapsulate, chelate, or encapsulate and chelate gadolinium in various forms. [0022] If the imaging technique of choice is CT, the contrast enhancing agent may comprise a CT-effective nanoparticle contrast enhancing agent, such as, for example, a liposomal agent comprising a liposome encapsulating a nonradioactive contrast enhancing agent, e.g., an iodinated nonradioactive contrast enhancing agent such as iohexol or iodixanol. For example, the nanoparticle contrast enhancing agent may comprise: liposomes, the liposomes comprising: a phospholipid (e.g., DPPC); a phospholipid that is derivatized with a polymer (e.g., a PEGylated phospholipid such as mPEG2000-DSPE); and cholesterol, wherein the liposomes encapsulate a nonradioactive iodinated contrast enhancing agent (e.g., iohexol and/or iodixanol). In one embodiment, the nanoparticle contrast enhancing agent is less than about 200 nm in average diameter. In one embodiment, the nanoparticle contrast enhancing agent is less than about 175 nm in average diameter. In one embodiment, the nanoparticle contrast enhancing agent is less than about 150 nm in average diameter. In one embodiment, the nanoparticle contrast enhancing agent is about 100 nm in average diameter. [0023] Once an image is obtained, a 3-D autocorrelation function may be applied to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum. In other words, in one embodiment, the 3-D autocorrelation function may be applied in a local sense, to a carefully selected subdomain, and the computation so 6 WO 2013/110013 PCT/US2013/022336 restricted, rather than calculating the autocorrelation function over the totality of the image. [0024] The method may further comprise comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for amyloid plaque deposition on a brain. [0025] Amyloid plaque deposits are a major neuropathological hallmark of Alzheimer's Disease, and manifest long before clinical symptoms are discernible. Thus, in one embodiment, the method may be useful for diagnosing Alzheimer's Disease in living patients. [0026] In one embodiment, nanoparticle contrast enhancing agent may be administered to a patient with subsequent MRI/CT and 3-D autocorrelation in order to establish a baseline spectrum of a patient's normal image and spectrum. In one embodiment, the patient is healthy when the baseline spectrum is established. Thus, subsequent administration may be used then, for example, to determine deviations from the baseline spectrum indicative of a disease state. In another embodiment, the patient may already have been diagnosed with a disease known or suspected to alter the patient's spectrum. In that case, subsequent administration may be used, for example, to gauge disease progression or to determine the effectiveness of treatment. In yet another embodiment, the baseline spectrum may reflect a sampling of healthy or diseased patients other than the patient under study. Thus, administration to the patient may be used, for example, to determine deviations from, or similarities to, the baseline spectrum or spectra indicative of a disease state or the absence of a disease state. 7 WO 2013/110013 PCT/US2013/022336 EXAMPLES [0027] Certain embodiments are described below in the form of examples. It is impossible to depict every potential application of the invention. Thus, while the embodiments are described in considerable detail, it is not the intention to restrict or in any way limit the scope of the appended claims to such detail, or to any particular embodiment. Example 1 - Preparation of Dual Gd Liposomes [0028] A lipid mixture comprising DPPC, Gd-DTPA-BSA, cholesterol, and mPEG2000-DSPE in the molar ratio 30:25:40:5 was dissolved in a chloroform:methanol (1:1 v/v) mixture. The solvent mixture was evaporated to dryness under vacuum and the lipid contents were hydrated with a solution of gadobenate dimeglumine (Multihance@, Gd-BOPTA, 500 mM Gd) to achieve a lipid concentration of 40 mM. The solution was stirred for 90 min at 60 'C and then sequentially extruded with five passes through a 400 nm Nuclepore membrane, seven passes through a 200 nm Nuclepore membrane, and ten passes through a 100 nm Nuclepore membrane. The resulting solution was diafiltered using a MicroKros@ module (Spectrum Laboratories, CA) of 500 kDa molecular weight cut-off to remove unencapsulated and unchelated Gd-chelate molecules. Size analysis of the liposomes indicated particles of approximately 100 nm in diameter. The low polydispersity index for various formulations indicated narrow size distributions. More than 95% of the liposomes were below 150 nm in diameter. Example 2 - MRI of mouse brain vasculature [0029] Cerebral angiograms were acquired in C57BL/6 mice using the dual Gd liposomes of Example 1 at a dose of 200 mg lipid/kg, injected intravenously. Imaging was conducted using FSPGR (Fast Spoilt Gradient) studies using a 5123 image 8 WO 2013/110013 PCT/US2013/022336 matrix, and the following parameters: repetition time (TR) = 20.0 ms; echo time (TE) = 3 ms; flip angle (FA) = 300; field of view (FOV) = 30mm x 30mm x 30mm; and images were generated with anisotropic voxel size of 60 i. Figure 1 shows an MRI image of the cranial vasculature in a mouse. In Figure 1, the entire cranial vasculature is clearly visible, including the circle of Willis and microvessels to about the 4th generation of bifurcation past the carotid. Example 3 - Morphological analysis [0030] To test the sensitivity of three morphometric techniques (multifractality, lacunarity, and 2-D autocorrelation), algorithms were implemented for each, in MATLAB. A 2-D section of the mouse brain vasculature from Figure 1 was used, and is shown in Figure 2. The TI weighted image with liposomal contrast was windowed to show vascular signal, but no soft tissue contrast. The section was placed dextro-rostral to centerline, and included vasculature in portions of the thalamus and hippocampus. To test the sensitivity of the morphometric measures to the presence of vascular anomalies, the sectional image was digitally manipulated to introduce below threshold "holes." Such holes would result when amyloid plaque deposits distort blood vessels. Three such cases were created, one in which a single large "hole" about 1mm x 0.5mm was created in the section; the second in which a single small hole, about 100[t x 200 [, was created; and the third in which multiple small holes were created. The holes were created using an algorithm that randomly generates clusters of spheres, the diameters of which are distributed normally about a mean, similar to a diffusion-limited aggregate, in order to simulate amyloid plaques. When the aggregates are superimposed on the voxel structure of the vascular image, they result in total and partial voxel occlusion, and the voxel intensities are either totally or fractionally reduced to baseline. 9 WO 2013/110013 PCT/US2013/022336 [0031] The results are shown in Figure 3a and Figure 3b, Cases A (normal), B (large hole), C (small hole), and D (several small holes). In each case, three morphometric analyses were performed: multifractral spectrum, lacunarity, and 2-D autocorrelation. The images clearly show multifractal behavior as evidenced by the characteristic inverted U shape of the spectrum. While introducing one large hole occupying about 2% of the area causes a dramatic change in the multifractal spectrum, such a large change is unrealistic to expect in actual amyloid deposition. At smaller area fractions, the multifractal spectrum is not sensitive. The lacunarity is less sensitive still, and only shows a difference for the largest hole set. 2-D autocorrelation spectra show very little change as well. Example 4 - Volume-Based Morphometry [0032] Cerebral vascular images from seven different mice were chosen. Three of the mice were APP/PSEN1 mice ranging from 14 to 21 months of age, and exhibiting significant cognitive deficit and signs of dementia. Two of the mice were non transgenic siblings in the same general age range. Two of the mice were normal C57BL/6 mice that were approximately ten months old. MR cerebral angiograms of each of these mice were acquired using the blood pool contrast agent of Example 1. Acquisition sequences were as described in Example 2. [0033] A volume was selected that was representative of the cortex and hippocampus as shown in Figure 2, and 3-D autocorrelation studies were conducted. The volume was C: 5 2A3 voxels. Volume C is a subset of Volume B. 3-D autocorrelation functions of the vascular maps within volume C are shown in Figure 4 (Figure 4 shows the 3-D autocorrelation functions of TI vascular maps). The three images in the top row (A, B, C) correspond to amyloid positive transgenic mice, while 10 WO 2013/110013 PCT/US2013/022336 the bottom row corresponds to the two age-matched amyloid negative mice (non transgenic siblings, D and E) and a control C57BL/6 12 month old (F). [0034] The characteristic structure of the amyloid positive mice is evident, with a marked fissure in the autocorrelation function, with C 2 rotational symmetry. In contrast, the normal and negative control mice exhibit a characteristic uniform structure, with also exhibiting C 2 symmetry. Thus, differentiating the two classes of structures is trivial; yet, the vascular structures themselves are visually unremarkable. [0035] The correlation function is an indication of the extent of correlation between any two points in the domain, with a spacing equal to the argument of the correlation function. Thus, a perfect correlation (always obtained at zero displacement) is 1, while an uncorrelated event exhibits a correlation of zero. Therefore, the origin in each of the images in Figure 4 is white, indicating that at zero displacement, the correlation is 1. Grayscale at other locations indicates a reduced correlation and black indicates no correlation. Thus, in the normal mice in the bottom row (D, E, F), there is a gentle drop off of correlation in all directions from the origin. The implication is that at any point in the vasculature (the domain sampled by the correlation function), there is a finite correlation with points surrounding it, as would be expected in a normal vascular map. [0036] The characteristic fissure in the correlation function of the amyloid positive mice corresponds to a precipitous drop in the correlation function in that narrow region of the fissure. The fissures are rotationally symmetric (C 2 ), suggesting that there is anisotropic point symmetry (D 2 n) in the vascular domain. Specific directions parallel to the fissures where there is no such drop off suggests that there are certain directions in the vascular domain where correlation is preserved. 11 WO 2013/110013 PCT/US2013/022336 [0037] F, also a normal mouse, shows somewhat different behavior, with small localized drops in correlation. The localized drops suggest very specific directional losses in correlation, but are clearly distinguishable from the drastic fissure structure of the amyloid positive cases. Example 5 - Simulation of Vascular Fissures [0038] To determine the implications of the fissure structure on the correlation function in the vascular domain, fissures were simulated, starting with a normal vascular map (similar to the procedure described in Example 3). Anisotropic point symmetry (D 2 n) would be consistent with blood vessels on which plaque-like dense objects were overlaid. Thus, in the axial direction of the vessels, there would be no drop in intensity, while at other angles there would be point symmetry about the reference center. On the other hand, if the plaques were not overlaid on the vessels, this symmetry would be destroyed. [0039] Two cases were simulated. First, synthetic plaques were randomly distributed in the volume, interrupting blood vessels where overlap occurred. Second, synthetic plaques were distributed preferentially along the blood vessels. In both cases, plaques were assumed to exhibit a loss of intensity in the MR image, and appear similar to normal tissue. [0040] Figure 5 shows an example of such "simulated" plaques overlaid on the otherwise normal vasculature of the selected tissue domain. Three cases are shown, with the average "plaque" size varying between 1 0 0 p and 3 0 0 p in radius, and occupying about 5% of the total volume of the tissue domain. The base case chosen is the vascular map for a normal 17 month old mouse (non-transgenic). The projections of the vascular images in the Z-direction (XY plane) and the Z-cross section (XY plane) of the autocorrelation function are shown. The autocorrelation 12 WO 2013/110013 PCT/US2013/022336 function develops rotationally symmetric nodules of correlation loss, but does not share any traits with the correlation functions of amyloid positive mice. [0041] On the other hand, Figure 6 shows the case of synthetic plaques distributed preferentially along the vasculature structures. The base case is the vascular map for a normal 17 month old mouse (non-transgenic). The plaques are shown with increasing image intensity (in multiples of Al, the 99% width of the unaltered image intensity distribution). Also shown in Figure 6 are a 3-D rendering of the simulated plaques, a projection of the vascular map in the Z direction (XY plane), and the Z-cross section of the autocorrelation function for each case. The correlation maps clearly develop the rotationally symmetric fissure structure that is characteristic of the amyloid positive cases. [0042] Thus, it may be concluded that: (1) normal mouse brain vasculature shows either a uniform autocorrelation function or, in some cases, due to noise in the vascular signal, an island structure in the correlation function, with local drops; and (2) amyloid mouse vasculature shows a characteristic fissure structure in the autocorrelation function, clearly distinguishable from all other forms. [0043] To the extent that the term "includes" or "including" is used in the specification or the claims, it is intended to be inclusive in a manner similar to the term "comprising" as that term is interpreted when employed as a transitional word in a claim. Furthermore, to the extent that the term "or" is employed (e.g., A or B) it is intended to mean "A or B or both." When "only A or B but not both" is intended, then the term "only A or B but not both" will be employed. Thus, use of the term "or" herein is the inclusive, and not the exclusive use. See Bryan A. Garner, A Dictionary of Modern Legal Usage 624 (2d. Ed. 1995). Also, to the extent that the terms "in" or "into" are used in the specification or the claims, it is intended to 13 WO 2013/110013 PCT/US2013/022336 additionally mean "on" or "onto." Finally, where the term "about" is used in conjunction with a number, it is intended to include ± 10% of the number. For example, "about 10" may mean from 9 to 11. [0044] As stated above, while the present application has been illustrated by the description of embodiments, and while the embodiments have been described in considerable detail, it is not the intention to restrict or in any way limit the scope of the appended claims to such detail. Additional advantages and modifications will readily appear to those skilled in the art. Therefore, the application, in its broader aspects, is not limited to the specific details and illustrative examples shown. Departures may be made from such details and examples without departing from the spirit or scope of the general inventive concept. 14
    权利要求:
    Claims (22)
    [1] 1. A method for characterizing a pathological lesion in a patient, the method comprising: introducing into the patient a contrast enhancing agent; subjecting the patient to at least one of MRI and CT to obtain an image; and applying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum.
    [2] 2. The method of claim 1, further comprising comparing the at least one
    [3] 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for the pathological lesion. 3. The method of claim 1, wherein the subjecting comprises subjecting the patient to MRI.
    [4] 4. The method of claim 3, wherein the contrast enhancing agent comprises: liposomes, the liposomes comprising: a phospholipid; a phospholipid that is derivatized with a polymer; and cholesterol, wherein the liposomes at least one of encapsulate and chelate gadolinium compounds.
    [5] 5. The method of claim 3, wherein the contrast enhancing agent comprises: liposomes, the liposomes comprising: DPPC; 15 WO 2013/110013 PCT/US2013/022336 Gd-DTPA-BSA; cholesterol; and mPEG2000-DSPE.
    [6] 6. The method of claim 3, wherein the contrast enhancing agent comprises a GdDTPA chelate derivative with a diphenylcyclohexylphosphate group.
    [7] 7. The method of claim 1, wherein the subjecting comprises subjecting the patient to CT.
    [8] 8. The method of claim 7, wherein the contrast enhancing agent comprises: liposomes, the liposomes comprising: a phospholipid; a phospholipid that is derivatized with a polymer; and cholesterol, wherein the liposomes encapsulate a nonradioactive iodinated contrast enhancing agent.
    [9] 9. The method of claim 7, wherein the contrast enhancing agent comprises: liposomes, the liposomes comprising: DPPC; mPEG2000-DSPE; and cholesterol, wherein the liposomes encapsulate at least one of iohexol and iodixanol.
    [10] 10. A method for detecting amyloid plaque deposition on a patient's brain, the method comprising: introducing into the patient a nanoparticle contrast enhancing agent; 16 WO 2013/110013 PCT/US2013/022336 subjecting the patient to at least one of MRI and CT to obtain an image; and applying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum.
    [11] 11. The method of claim 10, further comprising comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for amyloid plaque deposition on a brain.
    [12] 12. The method of claim 10, wherein the subjecting comprises subjecting the patient to MRI.
    [13] 13. The method of claim 12, wherein the nanoparticle contrast enhancing agent comprises: liposomes, the liposomes comprising: a phospholipid; a phospholipid that is derivatized with a polymer; and cholesterol, wherein the liposomes at least one of encapsulate and chelate gadolinium compounds.
    [14] 14. The method of claim 12, wherein the nanoparticle contrast enhancing agent comprises: liposomes, the liposomes comprising: DPPC; Gd-DTPA-BSA; cholesterol; and mPEG2000-DSPE. 17 WO 2013/110013 PCT/US2013/022336
    [15] 15. The method of claim 12, wherein the nanoparticle contrast enhancing agent comprises a GdDTPA chelate derivative with a diphenylcyclohexylphosphate group.
    [16] 16. The method of claim 10, wherein the subjecting comprises subjecting the patient to CT.
    [17] 17. The method of claim 16, wherein the nanoparticle contrast enhancing agent comprises: liposomes, the liposomes comprising: a phospholipid; a phospholipid that is derivatized with a polymer; and cholesterol, wherein the liposomes encapsulate a nonradioactive iodinated contrast enhancing agent.
    [18] 18. The method of claim 16, wherein the nanoparticle contrast enhancing agent comprises: liposomes, the liposomes comprising: DPPC; mPEG2000-DSPE; and cholesterol, wherein the liposomes encapsulate at least one of iohexol and iodixanol.
    [19] 19. A method for diagnosing Alzheimer's Disease in a patient, the method comprising: introducing into the patient a nanoparticle contrast enhancing agent, the nanoparticle contrast enhancing agent comprising: liposomes, the liposomes comprising: 18 WO 2013/110013 PCT/US2013/022336 DPPC; Gd-DTPA-BSA; cholesterol; and mPEG2000-DSPE; subjecting the patient to MRI to obtain an image; and applying a 3-D autocorrelation function to a subdomain of interest of the image to obtain at least one 3-D autocorrelation spectrum.
    [20] 20. The method of claim 19, further comprising comparing the at least one 3-D autocorrelation spectrum to a pre-existing 3-D autocorrelation spectrum that is characteristic for Alzheimer's Disease.
    [21] 21. The method of claim 19, wherein the molar ratio of the DPPC, the Gd DTPA-BSA, the cholesterol, and the mPEG2000-DSPE is about 30:25:40:5.
    [22] 22. The method of claim 19, wherein the liposomes have an average diameter of less than about 150 nm. 19
    类似技术:
    公开号 | 公开日 | 专利标题
    Panigrahy et al.2009|Neuroimaging of pediatric brain tumors: from basic to advanced magnetic resonance imaging |
    EP2756459B1|2020-12-09|Methods and compositions for objectively characterizing medical images
    D'souza et al.2015|Traumatic brain injury and the post-concussion syndrome: A diffusion tensor tractography study
    Algin et al.2010|Phase-contrast MRI and 3D-CISS versus contrast-enhanced MR cisternography on the evaluation of the aqueductal stenosis
    Tommasin et al.2019|Neuroimaging techniques to assess inflammation in multiple sclerosis
    Maravilla et al.1984|Magnetic resonance demonstration of multiple sclerosis plaques in the cervical cord
    Wetzel et al.2003|Imaging of the intracranial venous system with a contrast-enhanced volumetric interpolated examination
    Peter et al.2016|Novel assessment of global metabolism by 18F-FDG-PET for localizing affected lobe in temporal lobe epilepsy
    Haakma et al.2016|Diffusion tensor imaging of peripheral nerves in non-fixed post-mortem subjects
    Seitz et al.2002|Magnetic Resonance Imaging in Patients Diagnosed With Papilledema: A Comparison of 6 Different High‐Resolution T1‐and T2 |‐Weighted 3‐Dimensional and 2‐Dimensional Sequences
    Chinchure et al.2010|Structural and functional neuroimaging in intractable epilepsy
    Konishi et al.2016|Application of fiber tractography and diffusion tensor imaging to evaluate spinal cord diseases in dogs
    Haroun et al.2007|Arachnoid granulations in the cerebral dural sinuses as demonstrated by contrast-enhanced 3D magnetic resonance venography
    Ucar et al.2014|Evaluation of aqueductal patency in patients with hydrocephalus: three-dimensional high-sampling-efficiency technique | versus two-dimensional turbo spin echo at 3 Tesla
    Varoğlu et al.2010|Evaluation of patients with multiple sclerosis using a combination of morphometrical features and clinical scores
    Bydder1984|Nuclear magnetic resonance imaging of the brain
    Gasparotti et al.2011|Radiographic assessment of adult brachial plexus injuries
    RU2554213C1|2015-06-27|Method of estimating risk of ischemic impairment of cerebral blood flow
    Besson1990|Magnetic resonance imaging and its applications in neuropsychiatry
    Svensson et al.2021|Decreased tissue stiffness in glioblastoma by MR Elastography is associated with increased cerebral blood flow
    den Adel et al.2013|Self-gated CINE MRI for combined contrast-enhanced imaging and wall-stiffness measurements of murine aortic atherosclerotic lesions
    Yao et al.2018|Evaluation of Fiber Tracts for Brain Aging via Diffusion Tensor Imaging Tract Analyses: A Pliot Study
    Kim et al.2014|Analysis of Images According to the Fluid Velocity in Time-of-Flight Magnetic Resonance Angiography, and Contrast Enhancement Angiography
    Warner et al.2017|Imaging assessment of brain injury
    Salbinih et al.2019|Analysis of genu and splenium of the corpus callosum: comparison between healthy subjects with and without Leukoaraiosis
    同族专利:
    公开号 | 公开日
    MX366972B|2019-08-01|
    ES2855165T3|2021-09-23|
    US20130190605A1|2013-07-25|
    CN104081416A|2014-10-01|
    CA2848994A1|2013-07-25|
    EP2756459A1|2014-07-23|
    MX2014003621A|2014-08-22|
    JP2015505483A|2015-02-23|
    AU2013209437B2|2018-07-12|
    HK1202176A1|2015-09-18|
    JP6130401B2|2017-05-17|
    WO2013110013A1|2013-07-25|
    CN104081416B|2018-10-02|
    US10130326B2|2018-11-20|
    KR102064398B1|2020-01-09|
    BR112014010879A2|2017-06-13|
    WO2013110013A8|2018-08-02|
    EP2756459A4|2014-08-27|
    EP2756459B1|2020-12-09|
    KR20140114336A|2014-09-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5204085A|1985-01-08|1993-04-20|Mallinckrodt Medical, Inc.|Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents|
    US4893082A|1989-02-13|1990-01-09|Letcher Iii John H|Noise suppression in magnetic resonance imaging|
    IL113139D0|1994-03-28|1995-06-29|Nycomed Imaging As|Diagnostic compositions comprising imaging agents encapsulated in liposomes|
    US6071532A|1996-10-15|2000-06-06|Emory University|Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof|
    US6067465A|1997-11-26|2000-05-23|General Electric Company|System and method for detecting and tracking reference position changes with linear phase shift in magnetic resonance imaging|
    US7964192B1|1997-12-02|2011-06-21|Janssen Alzheimer Immunotherapy|Prevention and treatment of amyloidgenic disease|
    DE60017787T2|1999-11-30|2006-01-05|ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA, Tucson|RADIATION-SENSITIVE LIPOSOMES|
    US6463315B1|2000-01-26|2002-10-08|The Board Of Trustees Of The Leland Stanford Junior University|Analysis of cerebral white matter for prognosis and diagnosis of neurological disorders|
    AU1151702A|2000-10-04|2002-04-15|California Inst Of Techn|Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits|
    US6821504B2|2001-05-23|2004-11-23|New York University|Detection of alzheimer's amyloid by magnetic resonance imaging|
    US7138136B2|2002-03-05|2006-11-21|Cleveland State University|Agglomerated particles for aerosol drug delivery|
    MXPA04010255A|2002-04-19|2008-03-04|Univ Toronto|Immunological methods and compositions for the treatment of alzheimer's disease.|
    US20060120580A1|2002-09-04|2006-06-08|Sherif Makram-Ebeid|Characterizing, surfaces in medical imaging|
    US7605182B2|2003-05-01|2009-10-20|Aposense Ltd.|Compounds that selectively bind to membranes of apoptotic cells|
    EP2719394B1|2003-06-30|2015-07-29|Tel Aviv University Future Technology Development L.P.|Peptides for treating amyloid-associated diseases|
    US7208174B2|2003-12-18|2007-04-24|Hoffmann-La Roche Inc.|Liposome compositions|
    US7333845B2|2004-02-06|2008-02-19|Wake Forest University Health Sciences|Non-invasive imaging for determination of global tissue characteristics|
    US7713517B2|2004-04-21|2010-05-11|Marval Biosciences, Inc.|Compositions and methods for enhancing contrast in imaging|
    US8357351B2|2004-04-21|2013-01-22|Ananth Annapragada|Nano-scale contrast agents and methods of use|
    CA2587253A1|2004-07-02|2006-02-09|William E. Klunk|A method of diagnosing prodromal forms of diseases associated with amyloid deposition|
    US9320452B2|2004-07-06|2016-04-26|Mayo Foundation For Medical Education And Research|Magnetic resonance imaging of amyloid plaque in the brain|
    EP1793868B1|2004-09-23|2010-12-29|Guerbet|Liposomal contrast agents for cest imaging|
    WO2006120195A1|2005-05-12|2006-11-16|Bracco Imaging S.P.A.|Method for coding pixels or voxels of a digital image and a method for processing digital images|
    US20070160658A1|2005-10-20|2007-07-12|The Penn State Research Foundation|Delivery system for diagnostic and therapeutic agents|
    EP1780672A1|2005-10-25|2007-05-02|Bracco Imaging, S.P.A.|Method of registering images, algorithm for carrying out the method of registering images, a program for registering images using the said algorithm and a method of treating biomedical images to reduce imaging artefacts caused by object movement|
    US20090123047A1|2007-03-21|2009-05-14|Yfantis Spyros A|Method and system for characterizing prostate images|
    EP1982733A1|2007-04-17|2008-10-22|Bayer Schering Pharma Aktiengesellschaft|Use of a contrast agent for magnetic resonance imaging of endoleaks|
    AU2008278605A1|2007-07-26|2009-01-29|Nanoscan Imaging, Llc|Methods for imaging using improved nanoparticulate contrast agents|
    CN104274840A|2007-12-05|2015-01-14|马维尔生物科学公司|Nano-scale contrast agents and methods of use|
    US8192721B2|2007-12-13|2012-06-05|Verrow Pharmaceuticals, Inc.|Compositions useful for reducing toxicity associated with gadolinium-based contrast agents|
    CN102037004A|2008-01-08|2011-04-27|生物种属学股份公司|Glycoconjugation of polypeptides using oligosaccharyltransferases|
    ITMI20081052A1|2008-06-10|2009-12-11|Univ Milano Bicocca|LIPOSOMAS ABLE TO EFFECTIVELY TIE THE BETA-AMYLOID PEPTIDE|
    US20090311191A1|2008-06-13|2009-12-17|Ananth Annapragada|Imaging of atherosclerotic plaques using liposomal imaging agents|
    US20110208064A1|2008-07-31|2011-08-25|Ran Chongzhao|Curcumin Derivatives for Amyloid-Beta Plaque Imaging|
    US20100031378A1|2008-08-04|2010-02-04|Edwards Joel A|Novel gene disruptions, compositions and methods relating thereto|
    AR074760A1|2008-12-18|2011-02-09|Metabolex Inc|GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME.|
    EP2410990A4|2009-03-19|2015-05-20|Marval Biosciences Inc|Compositions and methods for enhancing contrast in imaging|
    JP5665040B2|2009-09-10|2015-02-04|学校法人上智学院|Displacement measuring method and apparatus, and ultrasonic diagnostic apparatus|
    ES2620177T3|2009-10-15|2017-06-27|Guerbet|Imaging agents and their use for in vivo diagnosis of neurodegenerative diseases, particularly Alzheimer's disease and derived diseases|
    US8679009B2|2010-06-15|2014-03-25|Flint Hills Scientific, Llc|Systems approach to comorbidity assessment|
    JP5746334B2|2010-06-16|2015-07-08|シマベイ セラピューティクス， インコーポレーテッド|GPR120 receptor agonist and use thereof|
    US8658614B2|2010-08-13|2014-02-25|The University of Texas Health Science Center|Aptamer-containing compositions and methods for targeting E-selectin|
    KR101845281B1|2011-03-02|2018-04-04|센술린, 엘엘씨|Vesicle compositions|
    EP2694116B1|2011-04-06|2018-06-13|Board of Regents of the University of Texas System|Lipid-based nanoparticles|
    GB201112056D0|2011-07-14|2011-08-31|Univ Leuven Kath|Antibodies|
    KR102064398B1|2012-01-20|2020-01-09|애나프라가다, 아난스|Methods and compositions for objectively characterizing medical images|
    US9377472B2|2012-04-30|2016-06-28|Amoneta Diagnostics|Biological complex specific for Alzheimer's disease detection in vitro and use thereof|
    RU2696559C2|2013-03-14|2019-08-05|Селтакссис, Инк.|Leukotriene a4-hydrolase inhibitors|
    BR112017007238A2|2014-10-08|2018-01-16|Texas Children's Hospital|amyloid plaque sister imaging using liposomes|EP2694116B1|2011-04-06|2018-06-13|Board of Regents of the University of Texas System|Lipid-based nanoparticles|
    KR102064398B1|2012-01-20|2020-01-09|애나프라가다, 아난스|Methods and compositions for objectively characterizing medical images|
    BR112017007238A2|2014-10-08|2018-01-16|Texas Children's Hospital|amyloid plaque sister imaging using liposomes|
    WO2019060258A1|2017-09-19|2019-03-28|University Of Cincinnati|Systems and methods for detecting small physiological or pathological changes using high resolution magnetic resonance imaging|
    CN108961210B|2018-05-24|2021-08-31|上海集成电路研发中心有限公司|Method for judging whether image is processed by algorithm|
    法律状态:
    2014-07-03| DA3| Amendments made section 104|Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ANNAPRAGADA, ANANTH AND STAROSOLSKI, ZBIGNIEW |
    2018-11-08| FGA| Letters patent sealed or granted (standard patent)|
    优先权:
    申请号 | 申请日 | 专利标题
    US201261589165P| true| 2012-01-20|2012-01-20||
    US61/589,165||2012-01-20||
    PCT/US2013/022336|WO2013110013A1|2012-01-20|2013-01-20|Methods and compositions for objectively characterizing medical images|
    [返回顶部]